Holen Sie sich die Stockscreener-App
168.55
1.95%
-3.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$171.90
Offen:
$172.6
24-Stunden-Volumen:
1.88M
Relative Volume:
1.63
Marktkapitalisierung:
$18.82B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
22.65
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
+0.98%
1M Leistung:
-5.65%
6M Leistung:
+8.55%
1J Leistung:
+16.85%
1-Tages-Spanne:
$167.16
$173.04
1-Wochen-Bereich:
$165.30
$178.86
52-Wochen-Spanne:
$140.71
$182.38
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
168.55 | 19.22B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
|
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
|
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics (NYSE:DGX) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat
Quest Diagnostics Incorporated Stock Analysis and ForecastPhenomenal capital gains - PrintWeekIndia
What analysts say about Quest Diagnostics Incorporated stockDynamic growth stocks - PrintWeekIndia
How high can Quest Diagnostics Incorporated stock price go in 2025High-performance investment picks - jammulinksnews.com
Quest Diagnostics Trading Volume Drops 31.43% to $364 Million Ranking 317th Despite Stock Price Rise - AInvest
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity - inkl
Quest Diagnostics’ revenue up 15.2% to USD 2.76B in Q2 2025 - Medical Buyer
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics (DGX) Price Target Raised by UBS, Rating Maint - GuruFocus
U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 - GlobeNewswire
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank Ana - GuruFocus
Quest Diagnostics Incorporated (NYSE:DGX) Q2 2025 Earnings Call Transcript - Insider Monkey
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank | D - GuruFocus
Is Quest Diagnostics Incorporated a good long term investmentConsistently exceptional gains - Autocar Professional
Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... - Yahoo.co
Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
DGX Q2 Deep Dive: Acquisitions, Advanced Diagnostics, and Utilization Trends Drive Growth - TradingView
What drives Quest Diagnostics Incorporated stock priceBreakthrough financial growth - jammulinksnews.com
Quest Diagnostics Lifts Outlook As Testing Demand Grows - Finimize
Quest Diagnostics Surges to 241st in Daily Rankings with $476 Million Turnover - AInvest
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Well Positioned to Benefit From Strong Medical Utilization - Morningstar
Quest Diagnostics Q2 EarningsQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics Reports Strong Q2 Earnings, Exceeds ExpectationsNews and Statistics - IndexBox
Quest Diagnostics rises on upbeat results, guidance raise (DGX:NYSE) - Seeking Alpha
Quest Diagnostics raises annual forecasts on strong diagnostic testing demand - whbl.com
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises - The Globe and Mail
Quest Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Quest Diagnostics: Q2 Earnings Snapshot - CTPost
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics' Q2 2025 Earnings: A Strategic Analysis of Its Position in the Evolving Diagnostic Services Landscape - AInvest
Quest Diagnostics Inc (DGX) Q2 2025 Earnings: EPS of $2.47 Beats Estimates, Revenue Hits $2.76 Billion - GuruFocus
Quest Diagnostics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com Canada
Quest Diagnostics (DGX) Boosts FY25 Revenue Outlook Amid Growth and Efficiency Gains | DGX Stock News - GuruFocus
Quest Diagnostics (DGX) Exceeds Revenue Expectations in Strong Q - GuruFocus
Quest (NYSE:DGX) Surprises With Q2 Sales - TradingView
Earnings Flash (DGX) Quest Diagnostics Incorporated Posts Q2 Adjusted EPS $2.62 per Share, vs. FactSet Est of $2.57 - MarketScreener
Quest Diagnostics Reports Second Quarter 2025 Financial Results - TradingView
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - PR Newswire
Quest Diagnostics Earnings Preview: EPS Estimate $2.57, Neutral Consensus Rating, and 12.46% Upside Potential. - AInvest
Quest Diagnostics Earnings Preview - Nasdaq
Should You Buy Quest Diagnostics Ahead Of Earnings? - Barchart.com
Should You Buy Quest Diagnostics Ahead of Earnings? - The Globe and Mail
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance? - TradingView
Quest (DGX) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.53%
1.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):